Dataset opportunity
Pfmmedical — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Pfmmedical, usable for Diagnostic AI and Computer Vision.
Score
68.4
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
63%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Medical Imaging market was valued at $1.8 billion in 2025, with a projected CAGR of 35.1% (2026-2033).
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
Medium
Accessibility
Restricted
Legal
Mixed ownership — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Pfmmedical holds a high-value Medical Imaging Dataset, featuring modalities such as MRI/Pathology imagery. This data, which includes associated `medical_records` and is managed through their proprietary secuTrial clinical trial system, is exceptionally well-suited for developing and training Diagnostic AI applications by providing rich, structured, and context-aware information.
The AI in Medical Imaging market is experiencing explosive growth, valued at $1.8 billion in 2025 and is projected to expand at a CAGR of 35.1%. [8] While access requires navigating strict GDPR compliance, clinical trial regulations, and shared data ownership, the rarity and quality of this high-sensitivity patient health information (PHI) make it an indispensable asset for buyers aiming to build a competitive advantage in this rapidly growing market. [8] ⚠ Diligence (valuable data, access to negotiate): Clinical study data is managed via their proprietary secuTrial system, requiring strict GDPR and clinical trial regulation compliance.; Data ownership may be shared with clinical study centers and research partners.; Medical device data (MRI/Pathology) involves high-sensitivity patient health information (PHI). · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves pfmmedical owns a valuable and specific medical imaging dataset, including proprietary MRI scans related to breast conservation therapy. The data is collected in a structured, research-grade environment for clinical studies, suggesting high quality and rich associated metadata. This type of specialized imaging data is in high demand for training diagnostic AI models in the rapidly growing medical AI market, which is projected to expand at over 35% annually.
See dimension details ↓- Evidence Strength86
5 evidence types, 5 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Buyer Demand95
Buyer demand is exceptionally high, driven by a rapidly expanding market for AI in medical imaging that is projected to grow at a 35.1% CAGR. [8]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility14
open/API access
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility32
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity58
proprietary domain data (open lowers rarity)
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume64
5 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/open (current)
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Right to License28
ownership=mixed, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 4 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ good target — Pfmmedical is a good target as it's a medium-sized family business whose core activity is manufacturing and selling physical medical devices, with no evidence of selling data or AI as a product.
- Deep Qualification80
⚠ needs review — pfmmedical is a medical device manufacturer that sells tools to healthcare providers. The data, including imaging, is generated and owned by its customers (hospitals, labs) using these tools, making direct data acquisition unlikely. [data is owned by the company's customers; licensing restricted]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
press
- “<div style="margin-bottom: 20px;"><img alt="" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" height="500" src="https://cdn.expresshealthcare.in/wp-content/uploads/2019/06/10133402/GettyImages-1005788478-e1786084507842.jpg" width="750" /></div> <p>Manipal Hospital Kanakapura Road has launched a Paediatrics Centre offering Super Specialty Services, bringing together more than a dozen paediatric medical disciplines under one roof to provide comprehensive care for newborns, children and adolescents. The new centre brings together specialists across the spectrum of child health”
- “<p>SpaceFlex Knee: progettato per muoversi, costruito per adattarsi   Preservare la mobilità articolare durante una revisione in due fasi può fare una vera differenza per il recupero del paziente e per il successo del trattamento.   Con SpaceFlex Knee, G21 propone una soluzione che combina modularità ed efficienza chirurgica, consentendo la creazione di distanziatori personalizzati […]</p> <p>L'articolo <a href="https://distrettobiomedicale.it/g21-spaceflex-knee-il-sistema-modulare-per-distanziatori-personalizzati-nella-revisione-del-ginocchio/">G21 SpaceFlex Knee: il sistema m”
- “Ein drahtloser Photovoltaikchip unter der Netzhaut soll bei fortgeschrittener trockener altersabhängiger Makuladegeneration (AMD) einen Teil des verlorenen zentralen Sehens ersetzen. Mit der CE-Kennzeichnung öffnet sich für das PRIMA-System nun der europäische Markt. Die zugrunde liegende Studie meldet deutliche Verbesserungen der Sehschärfe, zeigt aber auch die Risiken des Eingriffs und lässt Fragen zum Langzeitnutzen offen.”
Downloads / exports
The holder maintains structured tabular data, including product specifications and regulatory documents, which is valuable for training AI on medical device compliance and documentation.
Knowledge base / docs
Evidence of detailed data governance policies, including GDPR compliance, signals a mature approach to data handling and consent, increasing the trustworthiness of the dataset for AI buyers.
Medical records / imaging
The company uses a dedicated platform for data collection in clinical studies, indicating that the imaging data is well-structured and likely linked to corresponding patient information from questionnaires.
Image collection
The holder generates proprietary MRI images from its specialized system for intraoperative analysis, representing a high-value, niche dataset for developing advanced oncology AI.
Industrial data
The company captures time-series data from its manufacturing and sterilisation processes, indicating deep operational control and a potential source of industrial data for process optimization AI.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Pfmmedical Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market was valued at $1.8 billion in 2025, with a projected CAGR of 35.1% (2026-2033) (source: Grand View Research). [8]. Investment score 68.4/100 (confidence 0.63). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Mazzetti — Public Procurement Dataset Opportunity
View opportunity →healthcareHistosonics — Medical Imaging Dataset Opportunity
View opportunity →healthcareQuantadt — Medical Imaging Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- What is a Dataset Worth?3 min read
- How a Data Transaction Works3 min read
- What you are entitled to sell3 min read